Visomitin
(Synonyms: SKQ1溴化物,SKQ1) 目录号 : GC19377A mitochondrial antioxidant
Cas No.:934826-68-3
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: |
Panc02 cells are treated 48 h with different concentrations of Visomitin (SkQ1). Cell viability after Visomitin treatment is measured with an EZ4U Kit as described by the manufacturers. Briefly, 20,000 cells per well are seeded in 96-wellplates and let grow overnight. Afterwards, cells are treated without the medium exchange. A substrate compound from the kit is added and the cells are further incubated for 5 hr at 37°C to convert the yellow colored tetrazolium to its red formazan derivate by living cells. The absorbance is measured at 450 nm[1]. |
Animal experiment: |
Female C57BL/6 mice are used in this study. For experiments on both acute and chronic pancreatitis, mice are divided in three groups. Group A (acute pancreatitis (AP) n=8; chronic pancreatitis (CP) n=12) is treated with 5 nmol/kg Visomitin (SkQ1), group B (AP n=8; CP n=12) is the untreated control, and group C (AP n=8; CP n=7) is the sham group, which is injected intraperitoneally with 0.9% NaCl instead of cerulein and is therefore the negative control group without pancreatitis. For experiments on acute pancreatitis, mice are pretreated with Visomitin for 8 weeks prior to induction of pancreatitis. Mice designated for experiments on chronic pancreatitis receive Visomitin at the same concentration for 8 weeks in parallel with induction of pancreatitis[2]. |
References: [1]. Bazhin AV, et al. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Int J Cancer. 2016 Jul 1;139(1):130-9. |
Visomitin is a new antioxidant with the highest mitochondrion membrane penetrating ability and potent antioxidant capability.
Direct treatment of tumor infiltrating leukocytes with Visomitin (SkQ1) does not influence their cytotoxicity against Panc02 cells. While Visomitin does not affect viability of the cell lines, this drug at 500 nM concentration reduces heavily the proliferation of human PDAC cells[1].
Regarding systemic angiogenic factors, it is observed in serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice a decrease in KC in the group of continuous treatment with Visomitin (SkQ1). Treatment of the mice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the Visomitin treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. The Visomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined[1].
References:
[1]. Bazhin AV, et al. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Int J Cancer. 2016 Jul 1;139(1):130-9.
[2]. Weniger M, et al. The Analgesic Effect of the Mitochondria-Targeted Antioxidant SkQ1 in Pancreatic Inflammation. Oxid Med Cell Longev. 2016;2016:4650489.
Cas No. | 934826-68-3 | SDF | |
别名 | SKQ1溴化物,SKQ1 | ||
Canonical SMILES | O=C(C(CCCCCCCCCC[P+](C1=CC=CC=C1)(C2=CC=CC=C2)C3=CC=CC=C3)=C4)C(C)=C(C)C4=O.[Br-] | ||
分子式 | C36H42BrO2P | 分子量 | 617.6 |
溶解度 | DMSO : ≥ 29 mg/mL (46.96 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.6192 mL | 8.0959 mL | 16.1917 mL |
5 mM | 0.3238 mL | 1.6192 mL | 3.2383 mL |
10 mM | 0.1619 mL | 0.8096 mL | 1.6192 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。